HomeCompareNEMTF vs ABBV

NEMTF vs ABBV: Dividend Comparison 2026

NEMTF yields 0.97% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NEMTF wins by $2.47M in total portfolio value· pulled ahead in Year 6
10 years
NEMTF
NEMTF
● Live price
0.97%
Share price
$80.10
Annual div
$0.78
5Y div CAGR
96.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.57M
Annual income
$2,073,142.99
Full NEMTF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — NEMTF vs ABBV

📍 NEMTF pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNEMTFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NEMTF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NEMTF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NEMTF
Annual income on $10K today (after 15% tax)
$82.77/yr
After 10yr DRIP, annual income (after tax)
$1,762,171.54/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, NEMTF beats the other by $1,741,115.54/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NEMTF + ABBV for your $10,000?

NEMTF: 50%ABBV: 50%
100% ABBV50/50100% NEMTF
Portfolio after 10yr
$1.34M
Annual income
$1,048,957.38/yr
Blended yield
78.55%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

NEMTF
Analyst Ratings
2
Hold
Consensus: Hold
Altman Z
5.5
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NEMTF buys
0
ABBV buys
0
No recent congressional trades found for NEMTF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNEMTFABBV
Forward yield0.97%3.06%
Annual dividend / share$0.78$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR96.2%40.6%
Portfolio after 10y$2.57M$102.3K
Annual income after 10y$2,073,142.99$24,771.77
Total dividends collected$2.51M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: NEMTF vs ABBV ($10,000, DRIP)

YearNEMTF PortfolioNEMTF Income/yrABBV PortfolioABBV Income/yrGap
1$10,891$191.06$11,550$430.00$659.00ABBV
2$12,035$381.55$13,472$627.96$1.4KABBV
3$13,651$773.10$15,906$926.08$2.3KABBV
4$16,214$1,607.89$19,071$1,382.55$2.9KABBV
5$20,851$3,501.96$23,302$2,095.81$2.5KABBV
6← crossover$30,568$8,257.75$29,150$3,237.93+$1.4KNEMTF
7$54,906$22,198.43$37,536$5,121.41+$17.4KNEMTF
8$131,862$73,112.34$50,079$8,338.38+$81.8KNEMTF
9$463,053$321,960.93$69,753$14,065.80+$393.3KNEMTF
10$2,568,610$2,073,142.99$102,337$24,771.77+$2.47MNEMTF

NEMTF vs ABBV: Complete Analysis 2026

NEMTFStock

Nemetschek SE provides software solutions for architecture, engineering, construction, media, and entertainment markets in Germany, rest of Europe, the Americas, the Asia Pacific, and internationally. It operates through four segments: Design, Build, Manage, and Media & Entertainment. The Design segment offers software solutions primarily under the Allplan, Graphisoft, Solibri, Precast, Vectorworks, SCIA, dRofus, Data Design System, Frilo, and RISA brands for architects, designers, engineers, structural engineers, specialist planners, and landscape designers, as well as developers and general contractors. This segment provides building information modeling (BIM) solutions for computer aided design and computer aided engineering in 2D and 3D building design and imaging. The Build segment offers integrated complete 5D BIM solutions primarily under the Bluebeam brand that support bidding and awarding, invoicing, budgeting, scheduling, and cost calculation; and commercial enterprise resource planning solutions. This segment serves construction companies, developers, building supplies, and general contractors, as well as planning offices, architects, and civil engineers. The Manage segment provides commercial property management services under the Crem brand; and modular and integrated software solutions for property, facility, and workplace management under the Spacewell brand for facility and property managers, banks, and insurance and property companies; and intelligent smart building platform. The Media & Entertainment segment offers software solutions under the Maxon name for rendering 3D modeling, animation, and visual effects that are used in film, television, advertising, and video game productions, as well as in medicine, product design, and infographics. The company was founded in 1963 and is headquartered in Munich, Germany.

Full NEMTF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this NEMTF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NEMTF vs SCHDNEMTF vs JEPINEMTF vs ONEMTF vs KONEMTF vs MAINNEMTF vs JNJNEMTF vs MRKNEMTF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.